|
 Alydar Pharmaceuticals is pioneering its proprietary, novel Pheromics™ product platform, based on a unique library of biologically active and highly diverse Infochemicals, to fill the growing need for new therapeutic products to treat major human diseases and disorders.
Alydar will commercialize its infochemical-based drugs through corporate partnerships and collaborations with other pharmaceutical and biotechnology companies. Therapeutic targets include cardiovascular diseases, cancer, neurological and psychiatric diseases and disorders, and wound healing. These human diseases represent major and growing markets where there is a continuing need for innovative and more efficacious therapies.
|
 |
